9 registrations that name L-glutamine as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 9 registrations
Status
Phase
2US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 9 registrations
RecruitingNCT05972291
Mechanisms of Gulf War Illness
No phase
VA Office of Research and Development
About 80 people
Started Oct 16, 2023
In plain words A study of L-glutamine in people 18 to 65, run by VA Office of Research and Development. It plans to enroll about 80 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Gulf War Illness; Irritable Bowel Syndrome; Gastrointestinal Symptoms.
Veterans 18-65 years old with GWI and chronic GI symptoms (abdominal pain, diarrhea, bloating) that started during their deployment in the Persian Gulf
Veterans 18-65 years old with GWI and chronic GI symptoms (abdominal pain, diarrhea, bloating)
increased intestinal permeability on the lactulose/mannitol permeability test (ratio >0.07)
able and willing to cooperate with the study
The exclusion criteria are on the listing.
What it tests, as registered
Oral Glutamine; Control Arm
Registered summary
Many veterans with Gulf War Illness developed chronic gastrointestinal symptoms during their deployment to the Persian Gulf. The pathophysiologic mechanisms of these chronic gastrointestinal symptoms are not well understood but cause significant morbidity in veterans. Our proposed studies will provide an innovative and novel treatment trial for chronic gastrointestinal symptoms in veterans with Gulf War Illness that were deployed into war zones. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06617182
Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.
Phase 2
Yongquan Shi
About 150 people
Started Sep 30, 2024
In plain words A Phase 2 study of L-glutamine in people 18 to 80, run by Yongquan Shi. It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Radiation Enteritis.
Age 18-80 years old, gender is not limited;
Patients with hematochezia symptoms of chronic radiation intestinal injury: Due to the lack of diagnostic gold standard for radiation intestinal injury, a comprehensive analysis of clinical, endoscopic, imaging and histopathological…
The proportion of dominant defecation bleeding in total defecation times in the week before treatment is not less than 20%;
ECOG score: 0-2.
The exclusion criteria are on the listing.
What it tests, as registered
Thalidomide; Glutamine; Thalidomide+Glutamine
Registered summary
At present, there is still a lack of standard and effective treatment strategies and procedures for radiation intestinal injury. Studies have shown that thalidomide can effectively treat refractory gastrointestinal bleeding caused by vascular malformation. Therefore, The investigators designed a single-center, open-label, randomized controlled study to evaluate the efficacy and safety of thalidomide combined with glutamine in the treatment of radiation intestinal injury.
Where, as registered
No US site; China (1).
RecruitingNCT06027242
Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
No phase
National Taiwan University Hospital
About 120 people
Started Feb 21, 2023
In plain words A study of L-glutamine in people 20 and older, run by National Taiwan University Hospital. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: Gastric Cancer; Immunonutrition; Gastrostomy.
adult gastric cancer receiving gastrectomy
The exclusion criteria are on the listing.
What it tests, as registered
oral glutamine; Maltodextrin
Registered summary
Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT04883515
Effects of Oral Glutamine Supplementation on Insulin Resistance and Functional Intestinal Disorders in Obese Patients.
No phase
University Hospital, Rouen
About 110 people
Started Mar 1, 2023
In plain words A study of L-glutamine in people 18 to 65, run by University Hospital, Rouen. It plans to enroll about 110 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Obesity; Insulin Resistance.
Patients aged from 18 to 65 years
Patient with h grade II or III obesity (body mass index equal or higher than 35 kg/m2)
Patient with insulino-resistance (fasting glycaemia ≥ 1g/l et < 1.26 g/l)
Patient with irritable bowel syndrome (Rome IV criteria ≥ 2)
Obesity, which has a prevalence at 15% in France, is a major public health concern. Altered glycemic control and irritable bowel syndrome (IBS) are frequently observed in obese patients and lead to reduce the quality of life. In the last decades, the role of gut microbiota and intestinal permeability has been underlined in obesity, glycemic control and IBS. Interestingly, experimental and clinical data show that glutamine, an amino acid, is able to maintain or restore intestinal permeability in different conditions. The full summary is on the listing.
Where, as registered
No US site; France (1).
RecruitingNCT06291038
Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel Syndrome With Impaired Intestinal Permeability
No phase
University Hospital, Rouen
About 60 people
Started Oct 3, 2024
In plain words A study of L-glutamine in people 18 to 75, run by University Hospital, Rouen. It plans to enroll about 60 people at 4 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Irritable Bowel Syndrome.
Adult aged 18 to 75
Diarrheal irritable bowel syndrome (IBS-D), according to the Rome IV criteria (appendix 2)
Francis score > 175/500 at inclusion (corresponding to moderate to severe IBS)
Treatments for IBS stable for >1 month
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
• Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks; • Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.
Registered summary
Irritable bowel syndrome (IBS) affects approximately 5% of the general population and remains a daily problem in the practice of clinicians with inconsistent effectiveness of treatments while patients' expectations are high. One of the functional abnormalities described during IBS is increased intestinal permeability. This increase in intestinal permeability is primarily present in the diarrheal subtype (IBS-D) and can be measured using the lactulose/mannitol test. The full summary is on the listing.
Where, as registered
No US site; France (4).
RecruitingNCT05852990
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
Phase 3
Instituto Nacional de Cancerologia de Mexico
About 28 people
Started Mar 1, 2022
In plain words A Phase 3 study of L-glutamine in people 18 to 80, run by Instituto Nacional de Cancerologia de Mexico. It plans to enroll about 28 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Non-Small Cell Lung Cancer With EGFR Mutation.
Both sexes
≥ 18 years old
Pathologically confirmed diagnosis of NSCLC
Stage IIIB - IV by the American Joint Committee of Cancer Version 8.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Glutamine plus L. reuteri
Registered summary
This open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients with advanced non-small cell lung cancer (NSCLC) under tyrosine kinase inhibitors (TKIs) therapy. The main question it aims to answer is ¿What is the effect of glutamine plus L. reuteri added to an astringent diet in preventing diarrhea generated by TKI therapy? Patients will receive an astringent diet supplemented with 10 grams of glutamine and L. reuteri (100 million CFU). Researchers will compare the Glutamine plus L. The full summary is on the listing.
Where, as registered
No US site; Mexico (1).
Not yet recruitingNCT07864571
Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer
Phase 2
Jun Gong, MD
About 200 people
Starts Dec 2026 (estimated)
In plain words A Phase 2 study of L-glutamine in people 18 and older, run by Jun Gong, MD. It plans to enroll about 200 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Pancreatic Cancer.
Advanced or unresectable, histologically confirmed pancreatic ductal adenocarcinoma (PDAC, new diagnosis or recurrent, where recurrent tumor does not need to be histologically-confirmed) referred to Cedars-Sinai Medical Center (CSMC),…
Age ≥18 years
ECOG performance status ≤2 or Karnofsky performance status ≥60%
Demonstrate adequate organ and marrow function
7 more inclusion criteria and the exclusion criteria are on the listing.
This is a multi-institution, open-label, two-arm, prospective randomized controlled phase I trial with the purpose to investigate the clinical efficacy of combination gemcitabine, nab-paclitaxel, and L-glutamine compared to gemcitabine and nab-paclitaxel alone in treatment-naïve, unresectable or metastatic pancreatic cancer. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07053761
A Randomized Controlled Trial of Five - Flavor Sophora Flavescens Enteric - Coated Capsules for Radiation - Induced Proctitis After Pelvic Radiotherapy
Phase 2
Peking University First Hospital
About 124 people
Starts Jun 30, 2025 (estimated)
In plain words A Phase 2 study of L-glutamine in people 18 to 80, run by Peking University First Hospital. It plans to enroll about 124 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Radiation - Induced Proctitis.
What it tests, as registered
five - flavor sophora flavescens enteric - coated capsules plus glutamine and warm - water sitz baths; glutamine and warm - water sitz baths
Registered summary
The goal of this single - center, prospective, randomized controlled study is to assess the therapeutic effects of five - flavor sophora flavescens enteric - coated capsules on radiation - induced proctitis in patients who have undergone pelvic radiotherapy. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07287592
Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer.
Phase 3
Ain Shams University
About 70 people
Starts Dec 30, 2025 (estimated)
In plain words A Phase 3 study of L-glutamine in people 6 to 18, run by Ain Shams University. It plans to enroll about 70 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 to 18. Conditions: Neuropathy; Cancer.
No sex predilection.
Age: 6 years to 18 years
Children and adolescents diagnosed with hematological malignancy or solid tumors expected to receive a cumulative dose of 6 mg/m2 of VCR over a 12 week period (or >6 mg/m2 if individual VCR doses were capped at 2 mg) according to their…
Patients with score less than 5 on pediatric modified total neuropathy scale at Time 0
The exclusion criteria are on the listing.
What it tests, as registered
Glutamine (Pharmacological doses)
Registered summary
The goal of this clinical trial is to assess the efficacy of glutamine in preventing the occurrence of vincristine induced neuropathy and to compare the reduction in rate of any dose reductions and premature chemotherapy discontinuation rates due to peripheral neuropathy between those who treated with glutamine and those who did not. Participants will: receive glutamine in a dose of 6 g /m2 twice daily (up to a maximum of 10 g/dose) for 14 consecutive days from d 1 of induction and 14 days from d1 of continuation . The full summary is on the listing.